Clinical guidelines — the documents that tell physicians how to treat patients — are largely written by physicians with financial ties to the pharmaceutical industry. The conflicts of interest are pervasive and the guidelines reflect industry interests.

The Scope of the Problem

A 2011 study published in the Archives of Internal Medicine analyzed 17 major clinical guidelines and found:

  • 71% of guideline authors had financial relationships with the pharmaceutical industry
  • 90% of guideline authors had financial relationships with companies whose drugs were covered by the guidelines
  • Only 1 of 17 guidelines required authors to be free of conflicts of interest

A 2014 analysis of cardiovascular guidelines found that 56% of authors had received payments from pharmaceutical companies.

71% of clinical guideline authors have financial relationships with the pharmaceutical industry. 90% have relationships with companies whose drugs are covered by the guidelines they write.

How Conflicts Affect Guidelines

Financial conflicts of interest affect guidelines in predictable ways:

  • Lower treatment thresholds: Guidelines lower the threshold for treatment, increasing the number of patients who qualify for drug therapy
  • Higher treatment targets: Guidelines raise treatment targets (e.g., lower LDL goals, lower blood pressure goals), increasing the intensity of drug therapy
  • Favorable drug comparisons: Guidelines favor patented drugs over generic alternatives
  • Downplaying side effects: Guidelines minimize the risks of drugs made by companies that fund the authors

The Cholesterol Guideline Example

The 2013 ACC/AHA cholesterol guidelines dramatically expanded statin eligibility — from 43 million to 56 million Americans. The guidelines were written by a committee in which 8 of 15 members had financial ties to statin manufacturers.

The guidelines use a cardiovascular risk calculator that systematically overestimates risk, further expanding statin eligibility. Independent analyses found the calculator overestimates risk by 75-150%.

What Independent Evidence Shows

Independent systematic reviews (Cochrane Collaboration, Nordic Cochrane Centre) consistently find weaker evidence for drug therapy than industry-influenced guidelines suggest:

  • Statins: Primary prevention benefit is marginal; absolute risk reduction is very small
  • Antihypertensives: Benefit in mild hypertension is weak; side effects are common
  • Antidepressants: Benefit over placebo is clinically insignificant for mild-to-moderate depression

What Patients Can Do

Patients should ask their physicians:

  • Who wrote the guideline recommending this treatment?
  • Do the guideline authors have financial ties to the manufacturer?
  • What does the independent evidence (Cochrane reviews) say?